Welcoming Tom Doyle to the RIS Rx Family

Welcoming Tom Doyle to the RIS Rx Family

April 23, 2026

Gerard Rivera
Gerard Rivera Co-founder & CEO
Our PeopleOur Story
Get GTN Insights by Email
Alternative Funding Programs (AFPs) Are Getting the Headlines. But Your PAP Has a Bigger Problem.
Alternative Funding Programs (AFPs) Are Getting the Headlines. But Your PAP Has a Bigger Problem.

April 13, 2026

Stephen Hom
Stephen Hom Co-founder & COO
AFP-based leakageGTN Insights
What You Need to Know About the $90B Leakage Problem
What You Need to Know About the $90B Leakage Problem

April 1, 2026

Stephen Hom
Stephen Hom Co-founder & COO
GTN Insights
RIS Rx Introduces New Brand Platform: GTN Revenue Protection
RIS Rx Introduces New Brand Platform: GTN Revenue Protection

March 18, 2026

Chase Carpenter
Chase Carpenter VP, Marketing
Our StoryPress Releases
From Leakage to Leverage: How RIS Rx Is Redefining Patient Affordability at Scale
From Leakage to Leverage: How RIS Rx Is Redefining Patient Affordability at Scale

February 17, 2026

Gerard Rivera
Gerard Rivera Co-founder & CEO
GTN Insights
Welcoming Leslie Donato to our Board of Directors
Welcoming Leslie Donato to our Board of Directors

December 22, 2025

Gerard Rivera
Gerard Rivera Co-founder & CEO
Our PeoplePress Releases
Welcoming Stuart McGuigan to our Board of Directors
Welcoming Stuart McGuigan to our Board of Directors

December 17, 2025

Gerard Rivera
Gerard Rivera Co-founder & CEO
Our PeoplePress Releases
Grateful for the People Behind the Progress
Grateful for the People Behind the Progress

November 25, 2025

Gerard Rivera
Gerard Rivera Co-founder & CEO
Our People
Closing the Affordability Gap in Real Time
Closing the Affordability Gap in Real Time

November 25, 2025

Stephen Hom
Stephen Hom Co-founder & COO
Our Story
GTN Leakage Is Overwhelming Pharma Leaders—and It Shouldn’t Be
GTN Leakage Is Overwhelming Pharma Leaders—and It Shouldn’t Be

November 18, 2025

Gerard Rivera
Gerard Rivera Co-founder & CEO
PBM / Payer-based Leakage

Learn why the world‘s top pharmaceutical companies trust RIS Rx to protect their patients and improve GTN.